The FDA has approved a change to the brand name of the antidepressant formerly known as Brintellix (vortioxetine) because of reports that this name was being confused with Brilinta (ticagrelor), an anticoagulant (blood-thinning) medication. The new brand name of vortioxetine is Trintellix.
Trintellix tablets are the same as the Brintellix tablets. Aside from the name, no other changes were made to the label or packaging.
Vortioxetine is a type of antidepressant known as a multimodal serotonin reuptake inhibitor, which modulates serotonin. The FDA approved it in September 2013 to treat depression in adults. In July 2015, the FDA announced it had received reports of name confusion between Brintellix and Brilinta, and began to work with the drug’s manufacturer to change the brand name. The drug has been on the market as Trintellix since June 2016.
If you’ve been prescribed vortioxetine, ask your pharmacist to confirm that you are receiving the correct medication each time you have a prescription filled. Let him or her know immediately if the tablets do not look the same as they usually do.
Jeff Bauer is a healthcare journalist with expertise in psychiatry. He has served as editor of Current Psychiatry, a leading peer-reviewed clinical journal for psychiatrists and other mental health practitioners, and as educational content director for the U.S. Psychiatric and Mental Health Congress, the nation’s leading independent mental health continuing education conference.